Literature DB >> 11471552

Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE.

C J He1, T Koschinsky, C Buenting, H Vlassara.   

Abstract

BACKGROUND: Receptors for advanced glycation endproducts (AGE-R) mediate AGE turnover, but can also trigger inflammatory genes that promote diabetic tissue injury and diabetic complications (DC). High AGE levels and reduced AGE-R sites in kidneys of NOD mice prone to type 1 diabetes (T1D) and to renal disease (RD) suggested that impaired AGE-R function may contribute to RD in these mice.
MATERIALS AND METHODS: In this study, after confirming reduced AGE-R1 expression in NOD mouse peritoneal macrophages, we tested for differences in AGE-R1, -R2, and -R3 gene expression in 54 human subjects by RT-PCR and Western analysis. Fresh peripheral blood mononuclear cells (PBMN) were isolated from 36 persons: 18 T1D patients with severe RD (DC); 11 age-and DM-duration matched patients without DC (n-DC); and 7 normal volunteers (NL). EBV-transformed lymphoblasts were obtained from an additional 18 subjects (12 T1D patients, 6 with and 6 without DC, and 6 nondiabetics).
RESULTS: AGE-R1 mRNA and protein of PBMN from n-DC patients were enhanced (p < .05 versus NL) in proportion to serum AGE levels (sAGE) (p < .005 versus NL). In contrast, PBMN from DC patients exhibited no up-regulation of AGE-R1 mRNA or protein, despite higher sAGE levels (p < .005 versus NL). A similar unresponsiveness in AGE-R1 gene expression was observed in EBV-transformed lymphoblasts from DC patients versus NL (p < .01), but not in n-DC (p = NS). AGE-R2 and -R3 mRNA and protein levels were enhanced in both T1D groups (DC > n-DC) (n-DC AGE-R3, p < .05, DC AGE-R3, p < .05) compared to NL. AGE-R2 mRNA levels correlated with sAGE levels (r = .61, p < .05), and with creatinine clearance (r = -.63, p < .05). No differences were noted in AGE-R2 and -R3 mRNA expression in cultured cells.
CONCLUSIONS: The consistent pattern of elevated serum AGE and low expression of AGE-R1 gene in macrophages from T1D mice (NOD), fresh PBMN and EBV-transformed cells from T1D patients with advanced DC suggests ineffective regulation of R1-mediated AGE turnover, possibly of genetic basis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11471552      PMCID: PMC1950022     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  32 in total

Review 1.  Glycoxidation and diabetic complications: modern lessons and a warning?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells.

Authors:  Changyong Lu; John Cijiang He; Weijing Cai; Huixian Liu; Li Zhu; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

Review 3.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

4.  Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium.

Authors:  S McFarlane; J V Glenn; A M Lichanska; D A C Simpson; A W Stitt
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

5.  Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression.

Authors:  Weijing Cai; John Cijiang He; Li Zhu; Xue Chen; Sylvan Wallenstein; Gary E Striker; Helen Vlassara
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

Review 6.  Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

Authors:  Aowen Zhuang; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-06-06       Impact factor: 2.916

7.  Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons.

Authors:  Helen Vlassara; Jaime Uribarri; Luigi Ferrucci; Weijing Cai; Massimo Torreggiani; James B Post; Feng Zheng; Gary E Striker
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

8.  Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia.

Authors:  Massimo Torreggiani; Huixian Liu; Jin Wu; Feng Zheng; Weijing Cai; Gary Striker; Helen Vlassara
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

9.  AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease.

Authors:  Weijing Cai; Massimo Torreggiani; Li Zhu; Xue Chen; John Cijiang He; Gary E Striker; Helen Vlassara
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-02       Impact factor: 4.249

10.  Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1.

Authors:  Weijing Cai; Maya Ramdas; Li Zhu; Xue Chen; Gary E Striker; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.